- Home
- SKYE vs STKS Comparison
SKYE vs STKS Comparison
Compare SKYE & STKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- STKS
- Stock Information
- Founded
- SKYE 2012
- STKS 2004
- Country
- SKYE United States
- STKS United States
- Employees
- SKYE N/A
- STKS N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- STKS Restaurants
- Sector
- SKYE Health Care
- STKS Consumer Discretionary
- Exchange
- SKYE Nasdaq
- STKS Nasdaq
- Market Cap
- SKYE 108.5M
- STKS 109.7M
- IPO Year
- SKYE N/A
- STKS N/A
- Fundamental
- Price
- SKYE $4.25
- STKS $2.62
- Analyst Decision
- SKYE Buy
- STKS Hold
- Analyst Count
- SKYE 7
- STKS 3
- Target Price
- SKYE $15.50
- STKS $4.50
- AVG Volume (30 Days)
- SKYE 294.2K
- STKS 67.1K
- Earning Date
- SKYE 11-06-2025
- STKS 11-06-2025
- Dividend Yield
- SKYE N/A
- STKS N/A
- EPS Growth
- SKYE N/A
- STKS N/A
- EPS
- SKYE N/A
- STKS N/A
- Revenue
- SKYE N/A
- STKS $834,363,000.00
- Revenue This Year
- SKYE N/A
- STKS $26.58
- Revenue Next Year
- SKYE N/A
- STKS $5.37
- P/E Ratio
- SKYE N/A
- STKS N/A
- Revenue Growth
- SKYE N/A
- STKS 96.64
- 52 Week Low
- SKYE $1.14
- STKS $2.37
- 52 Week High
- SKYE $6.51
- STKS $5.26
- Technical
- Relative Strength Index (RSI)
- SKYE 66.34
- STKS 35.21
- Support Level
- SKYE $3.96
- STKS $2.65
- Resistance Level
- SKYE $4.35
- STKS $2.80
- Average True Range (ATR)
- SKYE 0.28
- STKS 0.12
- MACD
- SKYE 0.09
- STKS 0.02
- Stochastic Oscillator
- SKYE 91.15
- STKS 35.85
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About STKS The ONE Group Hospitality Inc.
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.